Better Therapeutics, Inc. (“Better Therapeutics”; NASDAQ: BTTX), a prescription digital therapeutics company developing cognitive behavioral therapy to address the root causes of cardiometabolic diseases, today announced the appointment of Deepti Sodhi Jaggi, PharmD, as its Chief Strategy Officer.
“Deepti has spent her career driving innovation at the intersection of healthcare and technology,” said Kevin Appelbaum, co-founder and Chief Executive Officer. “She brings a unique mix of intelligence, curiosity and courage to not be constrained by precedent. I look forward to working closely with her to make our vision of transforming the treatment of cardiometabolic diseases a reality.”
Dr. Jaggi joins Better Therapeutics with decades of experience focused on using technology to transform healthcare. Prior to Better Therapeutics, she served as Global Head of Patient Insights & Solutions at Astellas Pharmaceuticals and President & Chief Medical Officer at Clinakos Inc. Previously, Dr. Jaggi worked in business strategy roles for Johnson & Johnson, Genentech and Oracle Corp, among various other positions. She currently serves as a consultant to TPG Capital and sits on the Board of Directors for Technology Credit Union.
“This new role at Better Therapeutics culminates the array of expertise I’ve gained spanning the biopharma and technology sectors, and I look forward to making a meaningful impact on the lives of patients with cardiometabolic diseases working at this groundbreaking company,” said Dr. Jaggi, Chief Strategy Officer at Better Therapeutics. “This is a very forward-thinking and purpose driven team, building software which could be a catalyst for change in the way we address behavior-driven disease, and I’m honored to offer my guidance to help us get there.”
Dr. Jaggi received her doctorate in pharmacy from the University of Southern California and her MBA from Stanford University.
About Better Therapeutics
Better Therapeutics is a prescription digital therapeutics (PDT) company developing a novel form of cognitive behavioral therapy to address the root causes of cardiometabolic diseases. The company has developed a proprietary platform for the development of FDA-regulated, software-based solutions for type 2 diabetes, heart disease and other conditions. The cognitive behavioral therapy delivered by Better Therapeutics’ PDT is designed to enable changes in neural pathways of the brain so lasting changes in behavior become possible. Addressing the underlying causes of these diseases has the potential to dramatically improve patient health while lowering healthcare costs. Better Therapeutics clinically validated mobile applications are intended to be prescribed by physicians and reimbursed like traditional medicines. For more information visit: bettertx.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20211130005322/en/
+1 619 203 5391